Kazuaki Taguchi*, Toru Maruyama and Masaki Otagiri * Pages 1 - 15 ( 15 )
Carbon monoxide (CO), at low concentrations, can have a variety of positive effects on the body including anti-apoptosis, anti-inflammatory, anti-oxidative and anti-proliferative effects. Although CO has great potential for use as a potent medical bioactive gas, for it to exist in the body in stable form, it must be associated with a carrier. Hemoglobin (Hb) represents a promising material for use as a CO carrier because most of the total CO in the body is stored associated with Hb in red blood cells (RBC). Attempts have been made to develop an Hb-based CO carrying system using RBC and Hb-based artificial oxygen carriers. Some of these have been reported to be safe and to have therapeutic value as a CO donor in preclinical and clinical studies. In the present review, we overview the potential of RBC and Hb-based artificial oxygen carriers as CO carriers based on the currently available literature evidence for their use in pharmaceutical therapy against intractable disorders.
carbon monoxide, hemogoibn, intractable disorders, red blood cell, hemoglobin-based artificial oxygen carrier
Division of Pharmacodynamics, Faculty of Pharmacy, Keio University, Tokyo, Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto